| WU, Xiaohua |
FLAMES, NCT04169997: A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer |
|
|
| Active, not recruiting | 3 | 404 | RoW | IMP4927, Placebos | Impact Therapeutics, Inc. | Ovarian Cancer | 03/23 | 06/26 | | |
NCT05371301: Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer |
|
|
| Recruiting | 3 | 200 | RoW | Paclitaxel, Carboplatin, debulking surgery | Fudan University | Ovarian Cancer | 12/22 | 12/23 | | |
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer |
|
|
| Recruiting | 3 | 35 | RoW | Mirvetuximab Soravtansine, IMGN853, MIRV | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 04/23 | 12/23 | | |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
| Active, not recruiting | 3 | 366 | RoW | Olaparib, Matching placebo | AstraZeneca | Ovarian Cancer | 07/26 | 07/27 | | |
|
|
NCT06584032: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer |
|
|
| Recruiting | 3 | 412 | RoW | fruquintinib, HMPL-013, sintilimab, IBI308, paclitaxel, doxorubicin | Hutchmed | Advanced Endometrial Cancer | 01/29 | 06/29 | | |
CHIPRO, NCT04921527: Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer |
|
|
| Recruiting | 3 | 454 | RoW | chiauranib, CS2164, Placebo, Paclitaxel, Anzatax | Chipscreen Biosciences, Ltd. | Ovarian Cancer, Relapsed or Refractory, Chiauranib, Paclitaxel | 12/24 | 07/25 | | |
COMPASSION-16, NCT04982237: A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer |
|
|
| Active, not recruiting | 3 | 445 | RoW | AK104, paclitaxel, carboplatin, cisplatin, bevacizumab, Placebo | Akeso | Cervical Cancer | 12/25 | 12/25 | | |
BL-B01D1-310, NCT06994195: A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer |
|
|
| Not yet recruiting | 3 | 384 | RoW | BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Liposomal doxorubicin, Paclitaxel or Topotecan | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 06/27 | 12/27 | | |
NCT07168200: A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer |
|
|
| Recruiting | 3 | 720 | RoW | SHR-1316 Injection, Cisplatin Injection, Carboplatin Injection, Paclitaxel Injection, SHR-1316 Placebo Injection | Shanghai Shengdi Pharmaceutical Co., Ltd | Advanced Cervical Cancer | 04/28 | 12/28 | | |
FRAmework-01, NCT07213804: A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer |
|
|
| Recruiting | 3 | 1080 | Europe, Canada, Japan, US, RoW | LY4170156, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin, MIRV, Bevacizumab, Carboplatin | Eli Lilly and Company, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT) | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis | 04/28 | 08/31 | | |
COMPASSION-18, NCT05235516: A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer |
|
|
| Active, not recruiting | 3 | 636 | RoW | AK104, EBRT, BT, cisplatin, Placebo | Akeso | Locally Advanced Cervical Carcinoma | 05/26 | 05/29 | | |
NCT07177716: Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer |
|
|
| Not yet recruiting | 2/3 | 120 | RoW | LB1410, LB4330, Lenvatinib | L & L Bio Co., Ltd., Ningbo, China | Cervical Cancer | 12/28 | 12/28 | | |
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer |
|
|
| Completed | 2 | 170 | RoW | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer | 11/23 | 05/24 | | |
| Completed | 2 | 93 | RoW | IMP4297 | Impact Therapeutics, Inc. | Ovarian Cancer | 06/23 | 12/24 | | |
NCT03972722: Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 89 | RoW | GLS-010, Full-human anti-pd-1 monoclonal antibodies | Guangzhou Gloria Biosciences Co., Ltd. | Cervical Cancer | 05/22 | 05/23 | | |
|
NCT04836663: A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors |
|
|
| Recruiting | 2 | 90 | RoW | TQ-B3525 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer | 09/22 | 12/22 | | |
| Recruiting | 2 | 265 | RoW | SHR-1210, Camrelizumab, Famitinib, Famitinib Malate Capsule | Jiangsu HengRui Medicine Co., Ltd. | Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer | 12/22 | 12/22 | | |
NCT05043922: A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma |
|
|
| Recruiting | 2 | 86 | Japan, RoW | CYH33 | Haihe Biopharma Co., Ltd. | Ovarian Cancer, Recurrent Cancer | 06/23 | 06/23 | | |
NCT04593485: Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract |
|
|
| Recruiting | 2 | 40 | RoW | Camrelizumab for injection, Jiangsu Hengrui, SHR-1210 | Fudan University | Malignant Melanoma | 10/23 | 12/23 | | |
NCT02562365: Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer |
|
|
| Active, not recruiting | 2 | 130 | RoW | Etoposide, Cyclophosphamide, Carboplatin, VP-16,CTX,CBP | Xiaohua Wu MD | Ovarian Cancer | 11/23 | 11/23 | | |
NCT05479487: Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment |
|
|
| Not yet recruiting | 2 | 132 | NA | Fluzoparib+Apatinib, Fluzoparib Monotherapy | Xiaohua Wu MD | Relapsed Ovarian Cancer | 11/23 | 09/26 | | |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 12/25 | 12/25 | | |
| Active, not recruiting | 2 | 56 | RoW | SHR-1316, Cisplatin Injection/Carboplatin Injection, External Beam Radiotherapy (EBRT)/Brachytherapy, Paclitaxel Injection | Shanghai Shengdi Pharmaceutical Co., Ltd | Locally Advanced Cervical Cancer | 12/24 | 01/25 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 83 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
| Recruiting | 2 | 70 | RoW | WX390, WXFL10030390 | Shanghai Jiatan Pharmatech Co., Ltd | Solid Tumor | 06/25 | 06/26 | | |
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. |
|
|
| Recruiting | 2 | 90 | RoW | B013, Paclitaxel, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Platinum-resistant Recurrent Ovarian Cancer | 12/26 | 12/26 | | |
AK104-221, NCT06560112: An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer |
|
|
| Recruiting | 2 | 172 | RoW | AK104, Cadonilimab, AK112, Ivonescimab, Chemotherapy, Monotherapy Non-Platinum Chemotherapy chosen by the investigator | Akeso | Recurrent Ovarian Cancer | 05/26 | 05/27 | | |
BL-B01D1-204-11, NCT07054567: A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer |
|
|
| Recruiting | 2 | 206 | RoW | BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Pembrolizumab, Bevacizumab | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Cervical Cancer, Endometrial Cancer | 05/27 | 12/27 | | |
| Active, not recruiting | 2 | 240 | Europe, Canada, US, RoW | SKB264, Pembrolizumab, Keytruda | Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc., Clario | Solid Tumor | 11/27 | 12/27 | | |
BGB-290-102, NCT03333915: Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors |
|
|
| Completed | 1/2 | 128 | RoW | Pamiparib, BGB-290 | BeiGene | Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer | 08/20 | 08/21 | | |
|
|
|
|
|
| Recruiting | 1/2 | 18 | RoW | TC-E202 cells, TCR T Cells, IL-2, Fludarabine, Cyclophosphamide Capsules | TCRCure Biopharma Ltd., Fudan University | Cervical Carcinoma | 12/24 | 08/25 | | |
| Active, not recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/25 | 12/26 | | |
|
RAINFOL-01, NCT05579366: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) |
|
|
| Recruiting | 1/2 | 569 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer | 06/27 | 09/27 | | |
| Recruiting | 1/2 | 208 | RoW | SHR-4375 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Solid Tumors | 05/27 | 05/27 | | |
NCT06770881: JSKN033 in Chinese Subjects with Advanced Malignant Tumors |
|
|
| Not yet recruiting | 1/2 | 430 | NA | JSKN033 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Malignant Tumors | 12/26 | 12/27 | | |
BL-B01D1-202, NCT05803018: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies |
|
|
| Recruiting | 1/2 | 38 | RoW | BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Gynecological Malignant Tumor, Solid Tumor | 12/26 | 12/27 | | |
NCT06682780: A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours |
|
|
| Not yet recruiting | 1/2 | 320 | RoW | LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib, Lenvatinib | LaNova Medicines Limited | Advanced Solid Tumor | 12/27 | 12/29 | | |
NCT07061639: A Study of QLS5133 Monotherapy in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 212 | RoW | QLS5133 | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 07/27 | 04/28 | | |
NCT04586335: Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. |
|
|
| Terminated | 1 | 24 | US, RoW | CYH33, Olaparib | Haihe Biopharma Co., Ltd. | Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer | 02/23 | 02/23 | | |
KUNLUN-001, NCT06375187: Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | Engineering Tumor Infiltrating Lymphocytes, GC203 TIL | Shanghai Juncell Therapeutics | Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer, Lung Cancer | 11/25 | 05/27 | | |
NCT06428331: A Study of SKB518 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SKB518 for injection, SKB518 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Advanced Solid Tumors | 06/26 | 06/26 | | |
| Recruiting | 1 | 170 | RoW | SPH7485 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumor | 12/27 | 12/27 | | |
| Recruiting | 1 | 414 | US, RoW | SIM0505 for injection | NextCure, Inc., Shanghai Xianxiang Medical Technology Co., Ltd. | Advanced Solid Tumors | 02/28 | 08/28 | | |
| Recruiting | 1 | 20 | RoW | Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection | Fudan University, Cellular Biomedicine Group Ltd. | Cervical Cancer | 07/25 | 07/25 | | |
NCT07088588: Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 105 | RoW | SYN608 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, BRCA Mutation, HRR Deficiency | 07/28 | 10/28 | | |
NCT07156253: Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 110 | RoW | SYN818 and Olaparib will be administered | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, BRCA 1 /2 and / or HRD, Advanced Solid Tumors | 08/28 | 02/29 | | |
NCT05952947: HRYZ-T101 Injection for HPV18 Positive Solid Tumor |
|
|
| Recruiting | 1 | 32 | RoW | HRYZ-T101 Injection, Fludarabine + Cyclophosphamide | HRYZ Biotech Co. | Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis, Anal Cancer, Carcinoma of Vulva | 12/27 | 02/28 | | |
NCT04773327: Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies |
|
|
| Not yet recruiting | N/A | 150 | RoW | Mecapegfilgrastim Injection, PEG- rhg - csf | Xiaohua Wu MD | Gynecologic Malignant Tumor | 06/22 | 08/22 | | |
NCT04903665: PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I |
|
|
| Active, not recruiting | N/A | 495 | RoW | Multi-cancer early detection test | Fudan University, Guangzhou Burning Rock Bioengineering Ltd | Gynecologic Cancer | 08/22 | 12/22 | | |
SHAPE, NCT01658930: Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer |
|
|
| Completed | N/A | 700 | Europe, Canada, RoW | Radical Hysterectomy + pelvic lymph node dissection, Simple hysterectomy + pelvic lymph node dissection | Canadian Cancer Trials Group, Gynecologic Cancer Intergroup (GCIG), Canadian Institutes of Health Research (CIHR), Korean Gynecologic Oncology Group, Dutch Gynecologic Oncology Group, Cancer Trials Ireland, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Belgium Gynecologic Oncology Group, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Institute of Cancer Research, United Kingdom, Shanghai Cancer Centre Deptartment of Gynecologic Oncology Fudan University, Hertzen Moscow Scientific Research Institute of Oncology, Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Germany, Institut Claudius Regaud - Institute Universitaire du Cancer de Toulouse - Oncopole | Cervical Cancer | 03/23 | 11/24 | | |
NCT06001099: PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II |
|
|
| Recruiting | N/A | 2935 | RoW | | Fudan University, Guangzhou Burning Rock Dx Co., Ltd. | Gynecologic Cancer | 06/24 | 12/24 | | |
| Zhang, Jian |
HEARTRIP, NCT03809273: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI |
|
|
| Completed | 4 | 681 | RoW | Yangxinshi, Trimetazidine, Yangxinshi mimic, Trimetazidine mimic | Shenyang Northern Hospital | Percutaneous Coronary Intervention | 12/20 | 12/20 | | |
NCT04446819: Compression Gloves to Reduce Albumin-binding Paclitaxel Induced Peripheral Sensory and Motor Neurotoxicity (REMAINING) |
|
|
| Recruiting | 3 | 70 | RoW | Compression gloves | Fudan University | Peripheral Neuropathy | 01/22 | 06/22 | | |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
TQB2450-III-09, NCT04964479: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) |
|
|
| Recruiting | 3 | 375 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection, Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 12/22 | 03/23 | | |
NCT06143553: Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 168 | RoW | Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound) | Shanghai Yizhong Pharmaceutical Co., Ltd. | Metastatic Breast Cancer (MBC) | 12/25 | 12/25 | | |
NCT05346861: Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab |
|
|
| Recruiting | 3 | 240 | RoW | Trastuzumab plus chemotherapy, Trastuzumab in combination with pyrotinib plus chemotherapy | Fudan University | HER2-positive Breast Cancer, Metastatic Breast Cancer | 10/23 | 10/24 | | |
NCT05949801: Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure |
|
|
| Completed | 3 | 202 | RoW | Neucardin, Recombinant human Neuregulin-1 for Injection, Placebo, Excipients of recombinant human neuregulin-1 freeze dried for injection | Zensun Sci. & Tech. Co., Ltd. | Chronic Systolic Heart Failure | 08/24 | 10/24 | | |
| Recruiting | 3 | 224 | RoW | DB-1303/BNT323, T-DM1 | DualityBio Inc., BioNTech SE | HER2-positive Breast Cancer | 02/26 | 02/26 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 16700 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
BL-B01D1-307, NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Active, not recruiting | 3 | 418 | RoW | BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-Negative Breast Cancer | 06/26 | 06/26 | | |
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Triple Negative Breast Cancer | 08/26 | 06/27 | | |
GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. |
|
|
| Active, not recruiting | 3 | 211 | RoW | T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection | Changchun GeneScience Pharmaceutical Co., Ltd. | Breast Cancer Subjects | 11/25 | 03/26 | | |
SIMRISE, NCT06680921: A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer |
|
|
| Recruiting | 3 | 460 | RoW | SIM0270, Everolimus (Afinitor®), Exemestane tablets, Fulvestrant injection | Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Zaiming Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 08/28 | 08/28 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/26 | 03/29 | | |
NCT07146386: A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia |
|
|
| Not yet recruiting | 3 | 728 | RoW | H077 sustained-release tablet, Silodosin capsules Control Group | Shanghai Huilun Pharmaceutical Co., Ltd. | Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | 01/27 | 03/27 | | |
| Recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
| Recruiting | 2/3 | 1800 | RoW | Blinatumomab (Group A), high-dose methotrexate, Venetoclax (nonRand Group), cyclophosphamide, vincristine, dexamethasone, Blinatumomab (Group B) | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | 12/29 | 06/31 | | |
| Recruiting | 2/3 | 3000 | RoW | Blinatumomab, Dexamethasone, Prednisone, Asparaginase, Vincristine, Cyclophosphomide, Cytarabine, 6-MP, Methotrexate, Daunorubicin, Reinduction-2 omission, Chemo-light Maintenance 2 | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | 12/29 | 06/33 | | |
| Recruiting | 2/3 | 610 | RoW | Venetoclax, Asparaginase, Vincristine, Cyclophosphomide, Cytarabine, 6-MP, Methotrexate, Daunorubicin, Dexamethasone, Dasatinib, homoharringtonine | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma | 06/30 | 06/31 | | |
| Recruiting | 2 | 35 | RoW | SHR-1316, HTI-1088, Bevacizumab, Avastin, Cisplatin/Carboplatin, Bobei | Fudan University | Breast Cancer | 12/24 | 05/25 | | |
NCT05354076: Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo |
|
|
| Recruiting | 2 | 30 | RoW | doxorubicin hydrochloride liposome injection | Fudan University | Advanced Malignant Tumors | 06/22 | 11/22 | | |
NCT04192903: Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 55 | RoW | Chidamide combined with Cisplatin | Fudan University | Triple-negative Breast Cancer | 06/22 | 06/22 | | |
TEMPLATE, NCT04913571: Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study |
|
|
| Not yet recruiting | 2 | 265 | RoW | Eribulin, Tislelizumab | Fudan University | Triple Negative Breast Cancer | 06/22 | 06/23 | | |
NCT04517292: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 2 | 160 | RoW | Eribulin,cisplatin, Gemcitabine,cisplatin | Fudan University | Breast Cancer | 07/22 | 10/22 | | |
| Completed | 2 | 37 | RoW | HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib | Fudan University | Treatment Efficacy | 08/22 | 02/23 | | |
NCT04780347: Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer |
|
|
| Recruiting | 2 | 92 | RoW | Albumin-bound paclitaxel plus capecitabine, capecitabine | Fudan University | Breast Cancer | 12/22 | 02/23 | | |
NCT04745975: Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Fudan University | Triple Negative Breast Cancer | 01/23 | 01/23 | | |
KN026-205, NCT04778982: Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer |
|
|
| Terminated | 2 | 4 | RoW | KN026 combined with Palbociclib and Fulvestrant, combination | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | HER2-positive Metastatic Breast Cancer | 03/23 | 03/23 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NCT06332300: An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC |
|
|
| Withdrawn | 2 | 28 | RoW | Adebelimumab+Famitinib + FOLFIRI+Ariely | Jiangsu Province Nanjing Brain Hospital | NSCLC | 02/25 | 02/26 | | |
NCT06413615: A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 150 | RoW | FDA022-BB05 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/25 | 06/26 | | |
NCT06492005: A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 2 | 160 | RoW | 9MW2821, PD-1 inhibitior | Mabwell (Shanghai) Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 07/26 | 07/27 | | |
BL-B01D1-204-04, NCT06471205: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 52 | RoW | BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, PD-1 Monoclonal Antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-negative Breast Cancer | 07/26 | 07/26 | | |
| Recruiting | 2 | 200 | RoW | Camrelizumab, PD-1 antibody, Gemcitabine, Gem, Induction Cisplatin, DDP, intensity-modulated radiotherapy, IMRT, Concurrent cisplatin | Wei Jiang, Wuzhou Red Cross Hospital, Guangxi Nanxishan Hospital, Laibin People's Hospital, Lingshan people's Hospital | Nasopharyngeal Carcinoma | 04/25 | 04/26 | | |
NCT06042894: A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 58 | RoW | BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Breast Cancer | 12/26 | 12/27 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Completed | 1/2 | 84 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 08/24 | 08/24 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT06950086: Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 180 | RoW | TYK-00540 | TYK Medicines, Inc | HR-positive, HER2-negative Advanced Breast Cancer | 09/26 | 11/26 | | |
NCT05785728: A Study of DB-1202 Monotherapy in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 150 | RoW | DB-1202 | DualityBio Inc. | Advanced Solid Tumor | 02/24 | 02/24 | | |
NCT04282031: A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer |
|
|
| Recruiting | 1/2 | 224 | RoW | BPI-1178, Fulvestrant, Letrozole | Beta Pharma (Suzhou) Co., Ltd. | Advanced Solid Tumor, HR+/HER2- Breast Cancer | 12/24 | 06/25 | | |
| Recruiting | 1/2 | 181 | US, RoW | MRG004A | Shanghai Miracogen Inc. | Advanced or Metastatic Solid Tumors | 04/24 | 06/25 | | |
NCT05048160: A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm |
|
|
| Recruiting | 1/2 | 272 | RoW | Intravenous Infusion | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Neoplasm | 06/24 | 12/24 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Active, not recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 10/24 | 06/38 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 74 | RoW | TFX06 tablet | Shenzhen Yangli Pharmaceutical Technology Co., Ltd | ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer | 12/24 | 04/25 | | |
| Active, not recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/25 | 12/26 | | |
|
RAINFOL-01, NCT05579366: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) |
|
|
| Recruiting | 1/2 | 569 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer | 06/27 | 09/27 | | |
